Monalizumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | NKG2A |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies,[1] and other cancers.[2][3]
Mechanism of action
Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5]
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.